Trial Profile
Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 01 Feb 2018 Results assessing safety and efficacy published in the British Journal of Haematology
- 20 Jul 2016 Status changed from active, no longer recruiting to completed.
- 04 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Sep 2016.